Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies

Antimicrob Agents Chemother. 2015 Sep;59(9):5804-13. doi: 10.1128/AAC.00545-15. Epub 2015 Jul 13.

Abstract

An evaluation of the leishmanicidal activity in vitro and in vivo of hypericin, an expanded-spectrum photosensitizer found in Hypericum perforatum, is presented. Hypericin was evaluated against intracellular amastigotes in vitro of Leishmania (Viannia) panamensis. A topical formulation containing 0.5% hypericin was developed and assayed in vivo in a hamster model of cutaneous leishmaniasis. Results demonstrate that hypericin induces a significant antiamastigote effect in vitro against L. panamensis by decreasing the number of parasites inside infected cells. The topical formulation of 0.5% hypericin allows healing of L. panamensis-induced lesions upon a topical application of 40 mg/day plus visible-light irradiation (5 J/cm(2), 15 min), twice a week for 3 weeks.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anthracenes
  • Cell Line
  • Cricetinae
  • Humans
  • Leishmania / drug effects
  • Leishmania / pathogenicity
  • Leishmaniasis, Cutaneous / drug therapy*
  • Leishmaniasis, Cutaneous / therapy
  • Perylene / analogs & derivatives*
  • Perylene / therapeutic use
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use*
  • U937 Cells
  • Wound Healing / drug effects

Substances

  • Anthracenes
  • Photosensitizing Agents
  • Perylene
  • hypericin